Cumhurbaşkanı Yardımcısı Oktay başkanlığında aşı çalışmalarına ilişkin değerlendirme toplantıları sürüyor ogunhaber.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ogunhaber.com Daily Mail and Mail on Sunday newspapers.
Date Time
Innovative cancer therapy uses immune system to attack tumours
Imagine if you could re-engineer your immune system to target and attack cancer growing in your body. A new clinical trial led by a clinician researcher at the University of Alberta is doing just that.
Michael Chu, an assistant professor of oncology in the Faculty of Medicine & Dentistry, is leading a project to manufacture and test locally produced chimeric antigen receptor (CAR) T-cells for the treatment of leukemia and lymphoma.
CAR T-cell therapy is an innovative treatment that uses a patient’s own immune system to battle cancer cells. It’s a promising alternative to common treatments such as chemotherapy, radiation or surgery, and can be the only viable option for some patients.
The Society of Asian American Scientists in Cancer Research April 11 announced that it has honored 10 Indian American scientists for their outstanding cancer research.
Dr. Rajvir Dahiya, professor emeritus at U.C. San Franciscoâs School of Medicine and president of SAASCR, presented awards to these scientists April 11 during the American Association for Cancer Research annual meeting, according to the news release.
The awardees were Drs. Zaver M. Bhujwalla, Pankaj K. Singh, Neil Bhowmick, Anand Srivastava, Neeraj Saxena, Kaustubh Datta, Bhagavatula Moorthy, Nagi Kumar, Parameswaran Hari and Arun Sreekumar.
Bhujwalla is the William R. Brody Professor in the Russell H. Morgan Department of Radiology and Radiological Science of the Johns Hopkins University School of Medicine.
The findings, published in
Science Immunology, suggest only a single vaccine dose may be needed to produce a sufficient antibody response.
Researchers found that those who did not have COVID-19 called COVID naïve did not have a full immune response until after receiving their second vaccine dose, reinforcing the importance of completing the two recommended doses for achieving strong levels of immunity.
The study provides more insight on the underlying immunobiology of mRNA vaccines, which could help shape future vaccine strategies.
“These results are encouraging for both short- and long-term vaccine efficacy, and this adds to our understanding of the mRNA vaccine immune response through the analysis of memory B cells,” says senior author E. John Wherry, chair of the department of systems pharmacology and translational therapeutics at the University of Pennsylvania and director of the Penn Institute of Immunology in the Perelman School of Medicine.
By Sola Ogundipe
Those who have had COVID-19 may only need one vaccine dose, a new study suggests People who have recovered from COVID-19 had a robust antibody response after the first mRNA vaccine dose, but a little immune benefit after the second dose, according to new research from the Penn Institute of Immunology.
The findings, published in Science Immunology, suggest only a single vaccine dose may be needed to produce a sufficient antibody response.
The team found that those who did not have COVID-19 called COVID naïve did not have a full immune response until after receiving their second vaccine dose, reinforcing the importance of completing the two recommended doses for achieving strong levels of immunity.